| Literature DB >> 32767202 |
Shan S Qiu1, Tim Pruimboom2, Anouk J M Cornelissen2, Rutger M Schols2, Sander M J van Kuijk3, René R W J van der Hulst2.
Abstract
PURPOSE: Lymphedema is a debilitating condition that significantly affects patient's quality of life (QoL). The aim of this study was to assess the long-term outcomes after lymphaticovenous anastomosis (LVA) for extremity lymphedema.Entities:
Keywords: ICG; Indocyanine green; LVA; Lymph-ICF; Lymphedema; Quality of life
Year: 2020 PMID: 32767202 PMCID: PMC7568701 DOI: 10.1007/s10549-020-05839-4
Source DB: PubMed Journal: Breast Cancer Res Treat ISSN: 0167-6806 Impact factor: 4.872
Fig. 1Outpatient ICG lymphography. Preoperative planning using ICG lymphography in the outpatient clinic (a) Lymph vessels visualized by ICG lymphography; linear pattern to stardust pattern and (b) corresponding markings for incision site, based on ICG lymphography
Fig. 2Intraoperative picture of an end-to-end lymphaticovenous anastomosis
Demographics and clinical information
| Mean, SD | ||
|---|---|---|
| Patients | 100 | |
| Operations | 132 | |
| LVAs | 270 | |
| Gender | ||
| Female | 94 | |
| Male | 6 | |
| Age (years) | 57.1 ± 10.6 | |
| BMI (kg/m2) | 26.3 ± 4.9 | |
| Location of lymphedema | ||
| Arm | 85 | |
| Leg | 15 | |
| Etiology of lymphedema | ||
| Primary | 6 | |
| Secondary | 94 | |
| Affected side | ||
| Left | 46 | |
| Right | 54 | |
| ISL stagea | ||
| I | 4 | |
| IIA | 69 | |
| IIB | 25 | |
| III | 2 | |
| ICG stageb | ||
| 1 | 1 | |
| 2 | 19 | |
| 3 | 45 | |
| 4 | 26 | |
| 5 | 9 | |
| Follow-up (months) | 25.0 ± 10.9 | |
| Number of operations per patient | 1.3 ± 0.5 | |
| 1 operation | 70 | |
| 2 operations | 28 | |
| 3 operations | 2 | |
| Number of LVAs per patient | 2.7 ± 1.4 | |
| 1 LVA | 16 | |
| 2 LVAs | 39 | |
| 3 LVAs | 21 | |
| 4 LVAs | 15 | |
| 5 LVAs | 5 | |
| 6 LVAs | 1 | |
| 7 LVAs | 2 | |
| 8 LVAs | 1 | |
aInternational Society of Lymphology
bStage according to ICG lymphography
Fig. 3Mean Lymph-ICF preoperatively and postoperatively. Final Lymph-ICF measurement at last outpatient appointment for each patient (n = 100) over a mean follow-up 24.5 ± 10.9 months. Analysis: Paired Samples T-Test. *Statistically significant difference: A decrease of 10, 15, 12, 23, 15, and 14 in total score, physical function, mental function, household activities, mobility activities, and life and social activities were considered a statistically significant difference (p < 0.05) [29]
Preoperative versus postoperative total Lymph-ICF score for upper and lower extremities
| Follow-up (FU) period | FU (months) | Lymph-ICF scorea | |||
|---|---|---|---|---|---|
| Preoperative | Postoperativeb | Mean difference | |||
| < 2 months (n = 67)c | 1.3 ± 0.5 | 46.8 ± 17.6 | 27.3 ± 18.1 | − 19.5 | < |
| 2–6 months ( | 3.7 ± 1.0 | 43.0 ± 18.4 | 29.5 ± 19.6 | − 13.5 | < |
| 6–12 months ( | 8.0 ± 1.9 | 43.0 ± 18.8 | 26.4 ± 18.0 | − 16.6 | < |
| 12–24 months ( | 16.0 ± 3.6 | 45.3 ± 16.6 | 31.3 ± 18.6 | − 14.0 | < |
| > 24 months ( | 32.1 ± 6.4 | 39.6 ± 19.4 | 27.5 ± 20.6 | − 12.1 | < |
aCalculated using the Paired Samples T-Test
bMean difference in total Lymph-IC score between preoperative and postoperative score for the reported number of patients
cThe number of patients included in the analysis
Linear regression analysis with Lymph-ICF difference as dependent variable
| Independent variable | Lymph-ICF score differencea | ||
|---|---|---|---|
| 95% CI | |||
| Number of LVAs | − 2.89 | − 5.29 to − 0.50 | |
| ICG stage (1–3 vs 4–5) | − 3.22 | − 10.20 to 3.75 | |
| Circumference difference | − 0.09 | − 0.34 to 0.15 | |
| Follow-up (months) | 0.03 | − 0.28 to 0.34 | |
| Compression garment (no vs yes)c | − 5.24 | − 11.98 to 1.50 | |
aLymph-ICF score difference is calculated by subtracting the post-OR lymph-ICF score from the pre-OR lymph-ICF score
bUnstandardized beta (B):Calculated using linear regression analysis. A negative value means a decrease in Lymph-ICF, representing an increase in Quality of Life
cNo: discontinuation of compression garment, Yes: partial discontinuation and continuation of compression garment
Preoperative versus postoperative upper extremity lymphedema (UEL) indices (n = 85)
| FU period | FU (months) | Circumference (cm)a | |||
|---|---|---|---|---|---|
| Preoperative circumference | Postoperativeb | Difference | |||
| < 2 months ( | 1.34 ± 0.5 | 122.1 ± 20.5 | 122.4 ± 22.2 | + 0.3 ± 10.7 | |
| 2–6 months ( | 3.6 ± 0.9 | 124.4 ± 20.6 | 123.2 ± 21.7 | − 1.2 ± 8.8 | |
| 6–12 months ( | 8.1 ± 2.0 | 121.4 ± 17.7 | 123.4 ± 19.8 | + 2.0 ± 9.7 | |
| 12–24 months ( | 14.4 ± 3.0 | 122.1 ± 17.5 | 121.7 ± 21.1 | − 0.4 ± 8.7 | |
| > 24 months ( | 27.5 ± 4.3 | 119.8 ± 13.8 | 116.7 ± 15.0 | − 3.1 ± 8.7 | |
aCalculated using the Paired Samples T-Test
bMean difference in UEL-index preoperative and postoperative score for the reported number of patients
cThe number of patients included in the analyses
Compression garments and patient-reported outcomes
| Total | Arm | Leg | ||||
|---|---|---|---|---|---|---|
| Compression garments ( | ||||||
| Discontinuation (%) | 43 | 47.1 | 20 | |||
| Partial discontinuation (%) | 18 | 17.6 | 20 | |||
| Continuation (%) | 39 | 35.3 | 60 | |||
| Positive effectb ( | ||||||
| Yes (%) | 80 | 77.6 | 93.3 | |||
| No (%) | 20 | < | 22.4 | < | 7.6 | |
| Patients experiencing cellulitisa ( | ||||||
| Before operation (%) | 38.8 | 41 | 26.7 | |||
| After operation (%) | 23.5 | 26.5 | 6.7 | |||
| Cellulitis episodes per yeara ( | ||||||
| Before operation (Mean ± SD) | 1.1 ± 1.9 | 1.0 ± 1.6 | 1.4 ± 3.3 | |||
| After operation (Mean ± SD) | 0.5 ± 1.3 | 0.4 ± 1.0 | 0.6 ± 2.3 | |||
| MLD sessions per weeka ( | ||||||
| Before operation (Mean ± SD) | 1.3 ± 1.0 | 1.2 ± 0.8 | 1.9 ± 19 | |||
| After operation (Mean ± SD) | 0.8 ± 0.8 | < | 0.8 ± 0.71 | < | 0.9 ± 1.4 |
aCalculated using the Chi-Square test
bOutcome reported by patient
cCalculated using the McNemar test
dCalculated using the Paired Samples T-Test